Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma

Diane L. Persons*, Daniel A. Arber, Jeff A. Sosman, Kristen A. Borelli, Marilyn L. Slovak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


The HER-2/neu proto-oncogene is a useful prognostic and predictive biomarker in breast cancer. In addition, use of a humanized monoclonal antibody against HER-2/neu has recently been shown to have efficacy in the treatment of metastatic breast cancer. In order to examine the potential of HER-2/neu as a biomarker and as a target for HER-2/neu monoclonal antibody treatment in melanoma, we examined the HER-2/neu status in 40 advanced stage melanomas. Using fluorescence in situ hybridization for determining the gene amplification status and immunohistochemistry for detecting protein overexpression, we found that only one out of 40 cases of melanoma had an altered HER-2/neu status. These results demonstrated that HER-2/neu amplification and overexpression are not common in advanced stage melanoma and thus, HER-2/neu would have limited value as a biomarker or as a target for immunotherapy in melanoma.

Original languageEnglish (US)
Pages (from-to)1965-1968
Number of pages4
JournalAnticancer research
Issue number3 B
StatePublished - 2000


  • C-erbB-2
  • FISH
  • Fluorescence in situ hybridization
  • HER-2/neu
  • IHC
  • Immunohistochemistry
  • Melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma'. Together they form a unique fingerprint.

Cite this